Clinical trials with MTDQ /6,6'-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline)/ an antioxidant with radiation sensitizing effect. 1980

V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt

Daily doses of 1320 mg MTDQ have been administered orally to 7 patients for 100 subsequent days. Biological half-life and serum concentration measurements were performed. Function of vital organs, as well as routine laboratory findings revealed that MTDQ did not induce any toxic changes. The effect of MTDQ on the radiosensitivity of hypoxic tumor cells was studied in a combined treatment modality including 12 patients. The action on tumor regression was found encouraging. It has been found remarkable, too, that due to the effect of MTDQ and radiotherapy some of the nonspecific and general symptoms (e. g. pruritus) also disappeared.

UI MeSH Term Description Entries
D011804 Quinolines
D011838 Radiation-Sensitizing Agents Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. Radiation Sensitizer,Radiosensitizing Agent,Radiosensitizing Agents,Agents, Radiation-Sensitizing,Radiation Sensitizers,Radiation Sensitizing Agents,Radiation-Sensitizing Drugs,Radiation-Sensitizing Effect,Radiation-Sensitizing Effects,Radiosensitizing Drugs,Radiosensitizing Effect,Radiosensitizing Effects,Agent, Radiosensitizing,Agents, Radiation Sensitizing,Agents, Radiosensitizing,Drugs, Radiation-Sensitizing,Drugs, Radiosensitizing,Effect, Radiation-Sensitizing,Effect, Radiosensitizing,Effects, Radiation-Sensitizing,Effects, Radiosensitizing,Radiation Sensitizing Drugs,Radiation Sensitizing Effect,Radiation Sensitizing Effects,Sensitizer, Radiation,Sensitizers, Radiation,Sensitizing Agents, Radiation
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt
February 1980, Radiobiologia, radiotherapia,
V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt
January 1979, Die Nahrung,
V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt
January 1979, Die Nahrung,
V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt
November 1979, Xenobiotica; the fate of foreign compounds in biological systems,
V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt
April 1973, Biochemical pharmacology,
V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt
August 2003, Birth defects research. Part B, Developmental and reproductive toxicology,
V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt
August 1965, Gigiena truda i professional'nye zabolevaniia,
V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt
November 1979, Xenobiotica; the fate of foreign compounds in biological systems,
V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt
July 2022, Journal of biomedical research,
V Erdélyi, and V Bär, and Z Pollák, and J Fodor, and J Kralovánszky, and I Tóth, and I Hindy, and S Eckhardt
August 2023, Environmental science and pollution research international,
Copied contents to your clipboard!